Physicians' Academy for Cardiovascular Education

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD

Can targeting of IL-6 lead to CV protection in CKD?

5' education - May 19, 2021 - Prof. Paul Ridker, MD

Renal denervation as option for patients with hypertension despite medications

5' education - May 18, 2021 - Prof. Ajay Kirtane, MD

A call to solve the controversy on omega-3FAs trials

5' education - May 17, 2021 - Prof. Eileen Handberg, PhD

No superiority with NOAC compared to standard care following TAVI

5' education - May 17, 2021 - Jean-Philippe Collet, MD, PhD

Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI

5' education - May 16, 2021 - Prof. Freek Verheugt, MD

No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD

5' education - May 16, 2021 - William Schuyler Jones, MD

12-Months follow up of rapid hs -TnT protocol in ACS suspected patients

5' education - May 16, 2021 - Prof. Derek Chew, MD, PhD

No definite difference for primary endpoint but proven safety with ARNI in MI patients

5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD

Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction

10' education - May 11, 2021 - Prof. James Januzzi, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

A novel simplified algorithm to achieve LDL-c goal in very-high risk patients

15' education - May 11, 2021 - Prof. Luis Masana, MD, PhD and prof. Erik Stroes, MD, PhD

A new approach with LLT for very-high and extremely-high risk patients

5' education - May 6, 2021 - Prof. Maciej Banach, PhD, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Lipid-lowering therapies for statin-intolerant patients

15' education - May 5, 2021 - Prof. Maciej Banach, MD, PhD and prof. Ulrich Laufs, MD, PhD

Treatment algorithms for HFpEF

10' education - May 4, 2021 - Prof. John Cleland, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Solutions for improving LDL-c goal attainment - changing treatment patterns

15' education - Apr. 28, 2021 - Prof. Ulrich Laufs, MD, PhD and Derek Connolly, MD, PhD - Online CME

Recommendations for treatment algorithm of HFrEF

10' education - Apr. 26, 2021 - Andrew Coats, MD

PCSK9 inhibition in clinical practice

5' education - Apr. 21, 2021 - Prof. Maciej Banach, PhD, MD
Experts in dialogue - LDL-c goal attainment in high risk patients

Solutions for improving LDL-c goal attainment - advances in patient selection

15' education - Apr. 20, 2021 - Prof. Maciej Banach, MD, PhD, and prof. John Kastelein, MD, PhD

Weight loss maintenance in obesity more effective with GLP-1RA and exercise than either treatment alone

Literature - June 15, 2021 - Lundgren JR, et al. - N Engl J Med. 2021

Participants with obesity had, after 1 year, more effective body weight loss maintenance with a combination of liraglutide and exercise program compared to either single treatment alone.

Omega-3 fatty acids supplementation associated with increased risk of incident AF

Literature - June 15, 2021 - Lombardi M et al. - Eur Heart J Cardiovasc Pharmacother. 2021

This meta-analysis of five RCTs (REDUCE-IT, ASCEND, R&P, STRENGTH and OMEMI) showed that Omega-3 fatty acids supplementation is associated with an increased risk of incident AF, compared to placebo.

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD
A post hoc analysis of EMPA-REG OUTCOME explored potential mediators of the treatment effect of empagliflozin on kidney outcomes.

ERA-EDTA 2021 Prof. Wanner presents the results of a post hoc analysis of EMPA-REG OUTCOME, in which potential mediators of the treatment effect of empagliflozin on kidney outcomes were explored.

Biomarkers of inflammation predict HF hospitalization and adverse outcomes in AF

Literature - June 14, 2021 - Benz AP, et al. - J Am Heart Assoc. 2021

This combined cohort study suggested that IL-6 and hs-CRP levels were associated with HF hospitalization and adverse outcomes in patients with AF. The risk for HF hospitalization increased with increasing inflammation scores of both inflammation markers.

Improved quality of life with ferric carboxymaltose in iron-deficient patients, stabilized after acute HF

Literature - June 14, 2021 - Jankowska EA et al. - Eur Heart J. 2021

Treatment with IV ferric carboxymaltose in patients with iron deficiency who had stabilized after acute HF led to greater improvements in health-related quality of life from week 4 to week 24 after discharge, compared to placebo.

Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD

5' education - June 14, 2001 - Ype de Jong, MD
The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.

The predictive performance of six risk scores for ischemic stroke in patients with AF and CKD were validated. The Modified CHADS2 score showed good performance for discrimination and calibration in all kidney function categories.

Updated results of the SPRINT trial confirm previous findings

Literature - June 9, 2021 - The SPRINT Research Group
Additional analyses of all events through the end of the intervention period and post-trial observational follow-up data showed reduction of MACE and all-cause death with SBP target <120 mmHg compared to SBP target <140 mmHg.

Additional analyses of all events through the end of the intervention period and post-trial observational follow-up data showed reduction of MACE and all-cause death with SBP target <120 mmHg compared to SBP target <140 mmHg. With poll.

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD
Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.

Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.

Consensus document of HFA of ESC on tailored medical therapy for HFrEF patients

News - June 8, 2021

The Heart Failure Association of the European Society of Cardiology has published a consensus document with patient profiles that may be relevant for treatment implementation in HFrEF patients.

SGLT2 inhibitor for patients with HFrEF receives recommendation by CHMP for EU approval

News - June 8, 2021

Following the results from the EMPEROR-Reduced trial, the CHMP has issued a recommendation for empagliflozin in patients with symptomatic chronic HFrEF with or without T2DM to reduce the combined risk of CV death or HF hospitalization.

Europe-wide "Strong Kidneys" campaign

News - June 8, 2021
The ERA-EDTA has launched the

The ERA-EDTA has launched the "Strong Kidneys" campaign to raise awareness about kidney disease and its prevention.

Hematocrit is an important mediator of kidney benefit by SGLT2 inhibitor

News - June 7, 2021

ERA-EDTA 2021 A post hoc analysis of the EMPA-REG OUTCOME trial suggests that hematocrit is the key driver of the renal benefit observed with empagliflozin.